Given the higher response rate observed in the high TMB-patients, assessment of mismatch repair status and/or exome sequencing in tumour samples may help identify those patients possibly benefiting the most from administration of anti-PD-1/PD-L1 agents, in this way enabling a more personalized approach to treatment. The gene discussed is PDCD1; the disease is neoplasm.